162.51 USD
+8.15 (+5.28%)
162.51 USD
0 (0%)
Overall RGEN gets a fundamental rating of 5 out of 10. We evaluated RGEN against 58 industry peers in the Life Sciences Tools & Services industry. RGEN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RGEN had positive earnings in the past year.
In the past year RGEN had a positive cash flow from operations.
RGEN had positive earnings in 4 of the past 5 years.
Each year in the past 5 years RGEN had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 0.06%, RGEN is doing good in the industry, outperforming 68.97% of the companies in the same industry.
Looking at the Return On Equity, with a value of 0.08%, RGEN is in the better half of the industry, outperforming 70.69% of the companies in the same industry.
RGEN has a Return On Invested Capital (1.05%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 13.56%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROIC | 1.05% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
The Profit Margin of RGEN (0.25%) is better than 68.97% of its industry peers.
RGEN has a Operating Margin of 6.58%. This is in the better half of the industry: RGEN outperforms 62.07% of its industry peers.
RGEN's Operating Margin has declined in the last couple of years.
RGEN has a Gross Margin (51.59%) which is comparable to the rest of the industry.
RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
RGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, RGEN has more shares outstanding
Compared to 5 years ago, RGEN has more shares outstanding
RGEN has a better debt/assets ratio than last year.
2.2 Solvency
RGEN has an Altman-Z score of 7.43. This indicates that RGEN is financially healthy and has little risk of bankruptcy at the moment.
RGEN has a Altman-Z score of 7.43. This is amongst the best in the industry. RGEN outperforms 86.21% of its industry peers.
RGEN has a debt to FCF ratio of 5.05. This is a neutral value as RGEN would need 5.05 years to pay back of all of its debts.
RGEN has a better Debt to FCF ratio (5.05) than 67.24% of its industry peers.
RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
RGEN has a Debt to Equity ratio (0.26) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 7.43 |
ROIC/WACC0.11
WACC9.83%
2.3 Liquidity
RGEN has a Current Ratio of 8.36. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.36, RGEN belongs to the top of the industry, outperforming 89.66% of the companies in the same industry.
A Quick Ratio of 7.14 indicates that RGEN has no problem at all paying its short term obligations.
RGEN's Quick ratio of 7.14 is amongst the best of the industry. RGEN outperforms 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 21.17% over the past year.
The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
The Revenue has decreased by -8.54% in the past year.
RGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.62% yearly.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
Based on estimates for the next years, RGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 25.53% on average per year.
The Revenue is expected to grow by 15.90% on average over the next years. This is quite good.
EPS Next Y15.05%
EPS Next 2Y20.45%
EPS Next 3Y23%
EPS Next 5Y25.53%
Revenue Next Year15.25%
Revenue Next 2Y13.99%
Revenue Next 3Y14.29%
Revenue Next 5Y15.9%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
RGEN is valuated quite expensively with a Price/Earnings ratio of 97.90.
RGEN's Price/Earnings ratio is in line with the industry average.
RGEN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.45.
RGEN is valuated quite expensively with a Price/Forward Earnings ratio of 75.69.
RGEN's Price/Forward Earnings is on the same level as the industry average.
RGEN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 34.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 97.9 | ||
| Fwd PE | 75.69 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
The rest of the industry has a similar Price/Free Cash Flow ratio as RGEN.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 85.86 | ||
| EV/EBITDA | 80.49 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
RGEN's earnings are expected to grow with 23.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)6.5
PEG (5Y)13.78
EPS Next 2Y20.45%
EPS Next 3Y23%
5. Dividend
5.1 Amount
RGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
162.51
+8.15 (+5.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners98.43%
Inst Owner Change-81.57%
Ins Owners0.5%
Ins Owner Change-2.45%
Market Cap9.14B
Revenue(TTM)707.89M
Net Income(TTM)1.74M
Analysts80.71
Price Target191.18 (17.64%)
Short Float %6.32%
Short Ratio3.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.48%
Min EPS beat(2)-6.83%
Max EPS beat(2)7.78%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)4
Avg EPS beat(8)4.05%
EPS beat(12)8
Avg EPS beat(12)8.34%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)2
Avg Revenue beat(2)2.11%
Min Revenue beat(2)2.07%
Max Revenue beat(2)2.15%
Revenue beat(4)3
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)7
Avg Revenue beat(16)0.58%
PT rev (1m)5.29%
PT rev (3m)4.12%
EPS NQ rev (1m)-11.79%
EPS NQ rev (3m)-10.44%
EPS NY rev (1m)-0.89%
EPS NY rev (3m)-0.99%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-0.09%
Revenue NY rev (1m)0.61%
Revenue NY rev (3m)0.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 97.9 | ||
| Fwd PE | 75.69 | ||
| P/S | 12.92 | ||
| P/FCF | 85.86 | ||
| P/OCF | 69.85 | ||
| P/B | 4.39 | ||
| P/tB | 15.9 | ||
| EV/EBITDA | 80.49 |
EPS(TTM)1.66
EY1.02%
EPS(NY)2.15
Fwd EY1.32%
FCF(TTM)1.89
FCFY1.16%
OCF(TTM)2.33
OCFY1.43%
SpS12.58
BVpS37.03
TBVpS10.22
PEG (NY)6.5
PEG (5Y)13.78
Graham Number37.19
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROCE | 1.67% | ||
| ROIC | 1.05% | ||
| ROICexc | 1.43% | ||
| ROICexgc | 5.46% | ||
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% | ||
| FCFM | 15.04% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 37.9% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 117.95% | ||
| Profit Quality | 6126.58% | ||
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 | ||
| Altman-Z | 7.43 |
F-Score6
WACC9.83%
ROIC/WACC0.11
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
EPS Next Y15.05%
EPS Next 2Y20.45%
EPS Next 3Y23%
EPS Next 5Y25.53%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
Revenue Next Year15.25%
Revenue Next 2Y13.99%
Revenue Next 3Y14.29%
Revenue Next 5Y15.9%
EBIT growth 1Y163.23%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year75.45%
EBIT Next 3Y40.62%
EBIT Next 5Y36%
FCF growth 1Y9.1%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-10.84%
OCF growth 3Y13.8%
OCF growth 5Y21.15%
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status of REPLIGEN CORP (RGEN) stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the valuation of REPLIGEN CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for REPLIGEN CORP (RGEN) is 97.9 and the Price/Book (PB) ratio is 4.39.
Can you provide the expected EPS growth for RGEN stock?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 15.05% in the next year.